Raymond Martinez, DO
Family Medicine · Lihue, HINPI 1427080878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,914 and has fallen 95.5% since, to $85 in 2025.
Across 155 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$407
- Novo Nordisk$282
- Sanofi-aventis U.S. LLC$256
- Boehringer Ingelheim$249
- Abbott$209
- Lilly USA, LLC$170
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,60898%
- Education$412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $407 |
| Novo Nordisk | 24 | $282 |
| Sanofi-aventis U.S. LLC | 14 | $256 |
| Boehringer Ingelheim | 13 | $249 |
| Abbott | 10 | $209 |
| Lilly USA, LLC | 15 | $170 |
| Amgen(2 entities) | 8 | $169 |
| Merck | 8 | $152 |
| Pfizer | 6 | $117 |
| Novartis | 5 | $90 |
| Johnson & Johnson | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 5 | $77 |
| Radius Health, Inc. | 3 | $73 |
| E.r. Squibb & Sons, L.L.C. | 5 | $66 |
| Amarin Pharma, Inc. | 3 | $60 |
| Astellas Pharma US Inc | 2 | $44 |
| AbbVie(2 entities) | 2 | $41 |
| GSK | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $33 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,648 in reported general payments places this provider in the 85th percentile of 376 family medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 91 | $109,879 |
| SynjardyEmpagliflozin/Metformin Hcl | 38 | $61,277 |
| MounjaroTirzepatide | 46 | $58,557 |
| OzempicSemaglutide | 54 | $51,764 |
| XareltoRivaroxaban | 56 | $51,175 |
| EliquisApixaban | 58 | $50,556 |
| TrulicityDulaglutide | 33 | $43,465 |
| JanuviaSitagliptin Phosphate | 16 | $24,364 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $23,016 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $20,971 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $19,091 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $17,588 |
| Atorvastatin Calcium | 266 | $8,456 |
| FiaspInsulin Aspart (Niacinamide) | 13 | $6,999 |
| Rosuvastatin Calcium | 150 | $5,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy | $249 | $171,156129 claims |
| Lilly USA, LLCMounjaro, Trulicity | $170 | $102,02279 claims |
| MerckJanuvia, Janumet, Janumet Xr | $152 | $61,04453 claims |
| Novo NordiskOzempic, Fiasp | $282 | $58,76267 claims |
| Johnson & JohnsonXarelto | $81 | $51,17556 claims |
| PfizerEliquis | $117 | $50,55658 claims |
| AstraZenecaBreztri Aerosphere | $407 | $23,01631 claims |
| GSKTrelegy Ellipta | $33 | $20,97132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 376 family medicine providers in Hawaii.
Other family medicine in Lihue
- Rainier Dennis BautistaLihue$23K
- Dennis ScheppersLihue$4K
- Bernice YapLihue$3K
- Brian StolleyKihei$126K
- Vicente RamoHonolulu$34K
- Edward AlqueroWaipahu$24K
- Noelani HobbsWaipahu$23K
- Choon YeoHonolulu$20K
- Buddy FesterlingHilo$20K
- Roy KogaHilo$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.